Assessing Prostaglandin-Analog-Associated Uveitis in Childhood Glaucoma.

Cohort studyOcular immunology and inflammation· Jul 2026

Assessing Prostaglandin-Analog-Associated Uveitis in Childhood Glaucoma.

Marina B Zakhary Gad El Sayed, Reem H ElSheikh, Javaneh Abbasian … Abdelrahman M Elhusseiny

Read paper

GlaucomaCohort studyTreatmentQ2IF 1.7

Prostaglandin eye drops linked to lower uveitis risk than beta-blockers in childhood glaucoma

Assessing Prostaglandin-Analog-Associated Uveitis in Childhood Glaucoma.

Marina B Zakhary Gad El Sayed … Abdelrahman M Elhusseiny

Ocular immunology and inflammation · Jul 2026 · Q2 in Ophthalmology

Purpose

To evaluate the association between prostaglandin analogue (prostaglandin analogue) use and the development of uveitis in children and young adults with glaucoma.

Methods

Patients ≤ 20 years with glaucoma were identified using International Classification of Diseases, Tenth Revision (ICD-10) codes.

Results

prostaglandin users developed uveitis far less often than beta-blocker users

AHR by subgroup · 95% CI

More results

We identified 980 prostaglandin analogue initiators, 996 β-blocker initiators, and 477 carbonic anhydrase inhibitors initiators.

More results

Uveitis occurred rarely within 180 days across all treatment groups, with 11 uveitis events observed among the β-blocker cohort, and fewer than 10 uveitis events observed among each of the prostaglandin analogue and carbonic anhydrase inhibitors cohorts.

“

Conclusion

Among children and young adults with glaucoma, PGAs did not increase the hazard of uveitis during 180 days of follow-up and showed a lower hazard than β-blockers or carbonic anhydrase inhibitors.

Assessing Prostaglandin-Analog-Associated Uveitis in Childhood Glaucoma.

Assessing Prostaglandin-Analog-Associated Uveitis in Childhood Glaucoma.

Related papers